8-K: Ensysce Biosciences Stockholders Approve Share Issuance, Reverse Stock Split, and Director Elections at Annual Meeting

Ensysce Biosciences held its annual meeting on November 21, 2024, where stockholders approved key proposals including a share issuance, a reverse stock split, and the election of three Class III directors.

Summary

• Ensysce Biosciences held its annual meeting of stockholders on November 21, 2024.
• Stockholders approved the issuance of shares and warrants to certain investors, with 3,102,053 votes for, 210,141 against, and 180,836 abstentions.
• A reverse stock split was approved, allowing the Board to combine shares at a ratio between one-for-ten and one-for-forty, with 4,561,369 votes for, 1,989,571 against, and 937,153 abstentions.
• Three Class III directors, Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin, were elected to terms expiring in 2027.
• The appointment of Moss Adams LLP as the company's independent auditor for the fiscal year ending December 31, 2024, was ratified.
• A fifth proposal to adjourn the meeting to solicit additional proxies was not submitted to a vote.

Sentiment

Score: 6

Explanation: The document reflects a mix of positive and potentially negative actions. The share issuance is positive for funding, but the reverse stock split could be viewed negatively by some investors. The election of directors and ratification of the auditor are standard corporate governance procedures.

Positives

• The approval of the share issuance provides the company with additional capital.
• The reverse stock split could potentially increase the share price and make the stock more attractive to institutional investors.
• The election of the three directors ensures continuity and stability in the company's leadership.
• The ratification of Moss Adams LLP as the independent auditor provides assurance of financial oversight.

Negatives

• The reverse stock split could be perceived negatively by some investors as it reduces the number of outstanding shares.
• A significant number of votes were cast against the reverse stock split, indicating some shareholder concern.

Risks

• The reverse stock split could lead to a decrease in the stock price if not well received by the market.
• The company's ability to raise additional capital in the future may be affected by the reverse stock split.

Future Outlook

The company will proceed with the approved share issuance and reverse stock split, with the exact ratio to be determined by the Board.

Management Comments

• Dr. Lynn Kirkpatrick, President and Chief Executive Officer, signed the report on behalf of the company.

Industry Context

The approval of a reverse stock split is not uncommon for companies seeking to maintain their listing on exchanges like Nasdaq, and is often a sign of a company struggling to maintain a minimum share price. The share issuance is a common method for biotech companies to raise capital.

Comparison to Industry Standards

• Reverse stock splits are a common practice among companies listed on the Nasdaq, particularly those in the biotechnology sector, to maintain compliance with listing requirements, for example, companies like Cassava Sciences and Ocugen have recently undertaken reverse stock splits.
• The share issuance is a typical method for biotech companies to raise capital, similar to other companies in the sector such as Amylyx Pharmaceuticals and Biohaven Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the share issuance and reverse stock split.
• The election of directors ensures continued leadership for the company.
• The ratification of the auditor provides assurance of financial oversight.

Next Steps

• The company will proceed with the share issuance.
• The Board will determine the exact ratio for the reverse stock split.
• The newly elected directors will begin their terms.

Key Dates

Keywords

Annual Meeting, Share Issuance, Reverse Stock Split, Director Election, Moss Adams LLP, Nasdaq Listing Rule, Stockholders